Erick Lucera - May 20, 2024 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
EVP, CHIEF FINANCIAL OFFICER
Signature
/s/ Erick Lucera
Stock symbol
EDIT
Transactions as of
May 20, 2024
Transactions value $
-$125,404
Form type
4
Date filed
5/22/2024, 04:30 PM
Previous filing
Mar 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock -Sell -$125,404 -22,337 -16.05% $5.61 116,829 May 20, 2024 Direct F1

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 12, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 17, 2024. The sale does not represent a discretionary trade by the Reporting Person.